Tyler C. Liu is an associate in Sterne Kessler’s Biotechnology & Chemical Practice Group. He has experience in the preparation and filing of petitions for inter partes review (IPR) under the America Invents Act and has been involved in several IPR proceedings representing both patent owners and petitioners. He has also been involved in pharmaceutical patent litigations brought under the Hatch-Waxman Act.

Before joining Sterne Kessler, Tyler was in-house counsel at a generic pharmaceutical company, where he assisted in providing strategic planning regarding IPR matters and drafted IPR petitions, expert declarations, and other papers for several IPR proceedings.

During graduate school, Tyler studied missense polymorphisms in the gene encoding gonadotropin-releasing hormone among patients with metastatic prostate cancer at the National Cancer Institute of the National Institutes of Health. Tyler received his J.D. from The George Washington University Law School, his M.S. in biochemistry and molecular biology from Georgetown University, and his B.A. in molecular and cellular biology from the University of California, Berkeley.

  • J.D., The George Washington University Law School
  • M.S., Biochemistry and Molecular Biology, Georgetown University, Academic Excellence Award
  • B.A., Molecular and Cellular Biology, Neurobiology, minor in Chinese, University of California at Berkeley

  • District of Columbia
  • Texas
  • United States Patent & Trademark Office

  • Chinese (Mandarin)

Webinar

PTAB Playbook
Establishing Compelling Merits at the PTAB

Virtual, June 26, 2024 1:00 PM - 2:00 PM EDT

Related News & Insights

From Tyler C. Liu

Firm News

October 4, 2024

Sterne Kessler Achieves Major Victory for Hopewell Pharma Ventures in Two IPR Proceedings

Sterne, Kessler, Goldstein & Fox

Articles

March 11, 2024

Key Factors In Establishing Compelling Merits at the PTAB

Law360 David H. Holman, Ph.D., Tyler C. Liu

In the News

October 11, 2023

DNA Sequencing Patent Survives Guardant PTAB Challenge

Law360

In the News

March 14, 2022

Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

Bloomberg Law

In the News

March 14, 2022

Fed. Circ. Affirms PTAB's Ax of Acne Drug Patent

Law360

Reports

March 7, 2022

2021 PTAB Year in Review: Analysis & Trends

Sterne, Kessler, Goldstein & Fox Multiple Authors

Articles

March 7, 2022

Biologics at the PTAB: Statistics and Insights into Notable Biologics Decisions

Sterne, Kessler, Goldstein & Fox Deborah Sterling, Ph.D., Tyler C. Liu

Firm News

March 7, 2022

Sterne Kessler Publishes 2021 PTAB Year in Review: Analysis & Trends Report

Sterne, Kessler, Goldstein & Fox

Firm News

October 8, 2020

Sterne Kessler Client Wins 2020 Nobel Prize in Chemistry for CRISPR-Cas9 Technology

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Client Alert

July 7, 2020

IP Hot Topic: Patent Prosecution Tool Kit

Carla Ji-Eun Kim

Reports

July 7, 2020

2020 Patent Prosecution Tool Kit

Sterne, Kessler, Goldstein & Fox Multiple Authors

Articles

July 7, 2020

1.132 Declarations for Traversing Rejections

Sterne, Kessler, Goldstein & Fox Multiple Authors

In the News

June 1, 2020

Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB

Law360